BBI 5000

Drug Profile

BBI 5000

Alternative Names: BBI-5000

Latest Information Update: 07 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Brickell Biotech
  • Class Skin disorder therapies
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Atopic dermatitis

Most Recent Events

  • 01 Dec 2015 Brickell Biotech completes a phase I trial in Atopic dermatitis (In volunteers) in USA (NCT02590289)
  • 03 Feb 2015 BBI 5000 licensed to Brickell Biotech for the treatment of Atopic dermatitis
  • 03 Feb 2015 Phase-I clinical trials in Atopic dermatitis (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top